LivaNova (NASDAQ:LIVN) Price Target Increased to $72.00 by Analysts at Stifel Nicolaus

LivaNova (NASDAQ:LIVN) had its price objective increased by Stifel Nicolaus from $70.00 to $72.00 in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on LIVN. StockNews.com upgraded LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Needham & Company LLC restated a buy rating and set a $72.00 price objective on shares of LivaNova in a research report on Thursday, June 6th. Robert W. Baird boosted their target price on shares of LivaNova from $58.00 to $66.00 and gave the company a neutral rating in a report on Thursday, May 2nd. Finally, Mizuho raised their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, LivaNova has a consensus rating of Moderate Buy and an average price target of $67.17.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $53.61 on Thursday. The firm has a market cap of $2.90 billion, a PE ratio of -89.35 and a beta of 0.99. LivaNova has a one year low of $42.75 and a one year high of $64.47. The firm has a fifty day moving average of $55.07 and a 200 day moving average of $54.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.71 and a current ratio of 3.17.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. The company had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 EPS. As a group, research analysts predict that LivaNova will post 2.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Daniel Jeffrey Moore sold 56,623 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total transaction of $3,403,608.53. Following the completion of the transaction, the director now owns 27,534 shares of the company’s stock, valued at approximately $1,655,068.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is currently owned by insiders.

Institutional Trading of LivaNova

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Norges Bank purchased a new stake in shares of LivaNova in the 4th quarter valued at $26,064,000. Mesirow Institutional Investment Management Inc. purchased a new stake in LivaNova during the first quarter worth about $13,816,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of LivaNova during the fourth quarter worth about $8,330,000. Magnetar Financial LLC boosted its stake in shares of LivaNova by 24.5% in the first quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after purchasing an additional 148,178 shares during the period. Finally, abrdn plc acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $5,613,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.